| 기업공감원스톱서비스

유전자재조합 식품 lt;TEX gt;$ cdot$ lt;/TEX gt;식품첨가물안전성평가자료심사지침 제정 lt;TEX gt;$ cdot$ lt;/TEX gt;고시 - 식품의약품안전청고시 제1999-46호(`99. 8. 20) -

저자, 소속기관, 출판인, 간행물 번호, 발행연도, 초록, 원문UR, 첨부파일 순으로 구성된 논문저자 및 소속기관 정보표입니다
저자(한글)
저자(영문)
소속기관
소속기관(영문)
출판인
간행물 번호
발행연도	1999-01-01
초록	Gene therapy is becoming a very promising and feasible medical intervention as the understanding of human diseases extends to their molecular levels. Since the first US Food and Drug Administration (FDA)-approved human gene therapy protocol was approved in 1990, over 300 human clinical trial protocols had been approved worldwide so far. Even though some of the domestic gene therapy clinical trials also proved promising and more are awaiting, it should be emphasized that many safety aspects as well as effectiveness aspects should be considered during the development process. Moreover, there seems to be less restricted guidelines from the National Control Authority (NCA) in initiating human clinical trials. This article is intended to suggest some basis and points to consider in the development and evaluation of gene therapy products including antisense oligonucleotides pharmaceuticals.
원문URL	http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=JAKO199968317947211
첨부파일

기업조회